Deadly Brain Tumors May Have a Hidden Weakness—Scientists Just Found It

New research from the University of Virginia showcases a potential weakness in deadly brain tumors that could make them more susceptible to a groundbreaking drug delivery technique. Scientists at UVA Health's Focused Ultrasound Cancer Immunotherapy Center have discovered that gliomas, the most common primary brain tumors in adults, may respond better to this sound-wave-based method than healthy brain tissue.

This discovery alleviates concerns about the tumors potentially resisting the promising new treatment tool. Richard J. Price, co-director of the center and lead author of the study, emphasized the significance of these findings for patients. The results could better understand how existing brain tumor therapies could benefit from enhanced delivery to tumors using focused ultrasound.

Additionally, the findings may lead to the development of new drug and gene therapies optimized to work with focused ultrasound. Gliomas encompass a range of brain tumors, with glioblastoma being the deadliest form, with a mortality rate within five to 10 years in the U.S. The blood-brain barrier typically prevents harmful germs and toxins from entering the brain but blocks most cancer drugs during treatment.

Focused ultrasound presents a solution by temporarily and precisely opening the blood-brain barrier, allowing drugs to reach the tumor site without invasive procedures. The study, published in Radiology, confirms the technique's effectiveness in gliomas in laboratory mice and identifies an optimal size range for drug molecules—medium-sized ones performing best—helping scientists design new therapies tailored to paired with focused ultrasound. Further studies are required before the approach becomes available to patients.